Research and Markets: Global Oncology Drug Pipeline Capsule - 2012

Research and Markets: Global Oncology Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Oncology Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global oncology drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Bladder Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Renal Cancer.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Oncology Drug Pipeline Insights

- Bladder Cancer Drug Pipeline Insights

- Brain Cancer Drug Pipeline Insights

- Breast Cancer Drug Pipeline Insights

- Cervical Cancer Drug Pipeline Insights

- Colorectal Cancer Drug Pipeline Insights

- Gastric Cancer Drug Pipeline Insights

- Head and Neck Cancer Drug Pipeline Insights

- Non-small Cell Lung Cancer Drug Pipeline Insights

- Ovarian Cancer Drug Pipeline Insights

- Pancreatic Cancer Drug Pipeline Insights

- Renal Cancer Drug Pipeline Insights

- Tables and Figures included

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.